Insider Selling: Sensei Biotherapeutics (NASDAQ:SNSE) Major Shareholder Sells $26,671.95 in Stock

Sensei Biotherapeutics, Inc. (NASDAQ:SNSE) major shareholder James Peyer sold 3,105 shares of Sensei Biotherapeutics stock in a transaction on Monday, December 8th. The stock was sold at an average price of $8.59, for a total value of $26,671.95. Following the sale, the insider directly owned 158,254 shares of the company’s stock, valued at $1,359,401.86. This represents a 1.92% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Major shareholders that own at least 10% of a company’s stock are required to disclose their transactions with the SEC.

James Peyer also recently made the following trade(s):

• On Tuesday, December 9th, James Peyer sold 3,507 shares of Sensei Biotherapeutics stock. The stock was sold at an average price of $7.96, for a total transaction of $27,915.72.
• On Friday, December 5th, James Peyer sold 16,295 shares of Sensei Biotherapeutics stock. The shares were sold at an average price of $11.50, for a total transaction of $187,392.50.
• On Thursday, December 4th, James Peyer sold 5,000 shares of Sensei Biotherapeutics stock. The shares were sold at an average price of $9.06, for a total value of $45,300.00.

Sensei Biotherapeutics Stock Down 5.0%

Shares of Sensei Biotherapeutics stock opened at $8.55 on Friday. The firm’s 50-day moving average price is $9.81 and its two-hundred day moving average price is $8.65. The company has a market capitalization of $10.77 million, a price-to-earnings ratio of -0.45 and a beta of 0.32. Sensei Biotherapeutics, Inc. has a 12-month low of $5.00 and a 12-month high of $18.35.

Sensei Biotherapeutics (NASDAQ:SNSE) last announced its quarterly earnings data on Friday, November 14th. The company reported ($3.62) earnings per share for the quarter, topping the consensus estimate of ($4.11) by $0.49. On average, sell-side analysts expect that Sensei Biotherapeutics, Inc. will post -1.17 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of brokerages have issued reports on SNSE. HC Wainwright downgraded shares of Sensei Biotherapeutics from a “buy” rating to a “neutral” rating in a research report on Thursday, October 30th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Sensei Biotherapeutics in a report on Monday. One investment analyst has rated the stock with a Strong Buy rating, one has given a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $55.00.

Sensei Biotherapeutics Company Profile

Sensei Biotherapeutics, Inc, an immuno-oncology company, engages in the discovery and development of therapeutics for cancer patients. The company's Tumor Microenvironment Activated Biologics platform is designed to generate highly selective therapeutics that disable immunosuppressive signals or activate immunostimulatory signals selectively in the tumor microenvironment.